Global Vaginosis Drug Market Growth 2025-2031
The global Vaginosis Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.
United States market for Vaginosis Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Vaginosis Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Vaginosis Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Vaginosis Drug players cover Bayer, Pfizer, Sanofi, Piramal, Abbott, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Vaginosis Drug Industry Forecast” looks at past sales and reviews total world Vaginosis Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Vaginosis Drug sales for 2025 through 2031. With Vaginosis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaginosis Drug industry.
This Insight Report provides a comprehensive analysis of the global Vaginosis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaginosis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vaginosis Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaginosis Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaginosis Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaginosis Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Vaginosis Drug market?
What factors are driving Vaginosis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaginosis Drug market opportunities vary by end market size?
How does Vaginosis Drug break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.
United States market for Vaginosis Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Vaginosis Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Vaginosis Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Vaginosis Drug players cover Bayer, Pfizer, Sanofi, Piramal, Abbott, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Vaginosis Drug Industry Forecast” looks at past sales and reviews total world Vaginosis Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Vaginosis Drug sales for 2025 through 2031. With Vaginosis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Vaginosis Drug industry.
This Insight Report provides a comprehensive analysis of the global Vaginosis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vaginosis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Vaginosis Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vaginosis Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vaginosis Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Vaginosis Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Rx
- OTC
- Hospital
- Pharmacy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bayer
- Pfizer
- Sanofi
- Piramal
- Abbott
- Galderma
- Mission
- Alkem
- Xiuzheng
- Teva
- Perrigo
- West-Ward
- HPGC
- Yunnan Baiyao
- Starpharma
- Novel
- Edenvridge
What is the 10-year outlook for the global Vaginosis Drug market?
What factors are driving Vaginosis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaginosis Drug market opportunities vary by end market size?
How does Vaginosis Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaginosis Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Vaginosis Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Vaginosis Drug by Country/Region, 2020, 2024 & 2031
2.2 Vaginosis Drug Segment by Type
2.2.1 Rx
2.2.2 OTC
2.3 Vaginosis Drug Sales by Type
2.3.1 Global Vaginosis Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Vaginosis Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Vaginosis Drug Sale Price by Type (2020-2025)
2.4 Vaginosis Drug Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Vaginosis Drug Sales by Application
2.5.1 Global Vaginosis Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Vaginosis Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Vaginosis Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Vaginosis Drug Breakdown Data by Company
3.1.1 Global Vaginosis Drug Annual Sales by Company (2020-2025)
3.1.2 Global Vaginosis Drug Sales Market Share by Company (2020-2025)
3.2 Global Vaginosis Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Vaginosis Drug Revenue by Company (2020-2025)
3.2.2 Global Vaginosis Drug Revenue Market Share by Company (2020-2025)
3.3 Global Vaginosis Drug Sale Price by Company
3.4 Key Manufacturers Vaginosis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaginosis Drug Product Location Distribution
3.4.2 Players Vaginosis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VAGINOSIS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Vaginosis Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Vaginosis Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Vaginosis Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Vaginosis Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Vaginosis Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Vaginosis Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Vaginosis Drug Sales Growth
4.4 APAC Vaginosis Drug Sales Growth
4.5 Europe Vaginosis Drug Sales Growth
4.6 Middle East & Africa Vaginosis Drug Sales Growth
5 AMERICAS
5.1 Americas Vaginosis Drug Sales by Country
5.1.1 Americas Vaginosis Drug Sales by Country (2020-2025)
5.1.2 Americas Vaginosis Drug Revenue by Country (2020-2025)
5.2 Americas Vaginosis Drug Sales by Type (2020-2025)
5.3 Americas Vaginosis Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaginosis Drug Sales by Region
6.1.1 APAC Vaginosis Drug Sales by Region (2020-2025)
6.1.2 APAC Vaginosis Drug Revenue by Region (2020-2025)
6.2 APAC Vaginosis Drug Sales by Type (2020-2025)
6.3 APAC Vaginosis Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaginosis Drug by Country
7.1.1 Europe Vaginosis Drug Sales by Country (2020-2025)
7.1.2 Europe Vaginosis Drug Revenue by Country (2020-2025)
7.2 Europe Vaginosis Drug Sales by Type (2020-2025)
7.3 Europe Vaginosis Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaginosis Drug by Country
8.1.1 Middle East & Africa Vaginosis Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Vaginosis Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Vaginosis Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Vaginosis Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaginosis Drug
10.3 Manufacturing Process Analysis of Vaginosis Drug
10.4 Industry Chain Structure of Vaginosis Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaginosis Drug Distributors
11.3 Vaginosis Drug Customer
12 WORLD FORECAST REVIEW FOR VAGINOSIS DRUG BY GEOGRAPHIC REGION
12.1 Global Vaginosis Drug Market Size Forecast by Region
12.1.1 Global Vaginosis Drug Forecast by Region (2026-2031)
12.1.2 Global Vaginosis Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Vaginosis Drug Forecast by Type (2026-2031)
12.7 Global Vaginosis Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Bayer
13.1.1 Bayer Company Information
13.1.2 Bayer Vaginosis Drug Product Portfolios and Specifications
13.1.3 Bayer Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bayer Main Business Overview
13.1.5 Bayer Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Vaginosis Drug Product Portfolios and Specifications
13.2.3 Pfizer Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Vaginosis Drug Product Portfolios and Specifications
13.3.3 Sanofi Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Piramal
13.4.1 Piramal Company Information
13.4.2 Piramal Vaginosis Drug Product Portfolios and Specifications
13.4.3 Piramal Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Piramal Main Business Overview
13.4.5 Piramal Latest Developments
13.5 Abbott
13.5.1 Abbott Company Information
13.5.2 Abbott Vaginosis Drug Product Portfolios and Specifications
13.5.3 Abbott Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Abbott Main Business Overview
13.5.5 Abbott Latest Developments
13.6 Galderma
13.6.1 Galderma Company Information
13.6.2 Galderma Vaginosis Drug Product Portfolios and Specifications
13.6.3 Galderma Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Galderma Main Business Overview
13.6.5 Galderma Latest Developments
13.7 Mission
13.7.1 Mission Company Information
13.7.2 Mission Vaginosis Drug Product Portfolios and Specifications
13.7.3 Mission Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Mission Main Business Overview
13.7.5 Mission Latest Developments
13.8 Alkem
13.8.1 Alkem Company Information
13.8.2 Alkem Vaginosis Drug Product Portfolios and Specifications
13.8.3 Alkem Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Alkem Main Business Overview
13.8.5 Alkem Latest Developments
13.9 Xiuzheng
13.9.1 Xiuzheng Company Information
13.9.2 Xiuzheng Vaginosis Drug Product Portfolios and Specifications
13.9.3 Xiuzheng Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Xiuzheng Main Business Overview
13.9.5 Xiuzheng Latest Developments
13.10 Teva
13.10.1 Teva Company Information
13.10.2 Teva Vaginosis Drug Product Portfolios and Specifications
13.10.3 Teva Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Teva Main Business Overview
13.10.5 Teva Latest Developments
13.11 Perrigo
13.11.1 Perrigo Company Information
13.11.2 Perrigo Vaginosis Drug Product Portfolios and Specifications
13.11.3 Perrigo Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Perrigo Main Business Overview
13.11.5 Perrigo Latest Developments
13.12 West-Ward
13.12.1 West-Ward Company Information
13.12.2 West-Ward Vaginosis Drug Product Portfolios and Specifications
13.12.3 West-Ward Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 West-Ward Main Business Overview
13.12.5 West-Ward Latest Developments
13.13 HPGC
13.13.1 HPGC Company Information
13.13.2 HPGC Vaginosis Drug Product Portfolios and Specifications
13.13.3 HPGC Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 HPGC Main Business Overview
13.13.5 HPGC Latest Developments
13.14 Yunnan Baiyao
13.14.1 Yunnan Baiyao Company Information
13.14.2 Yunnan Baiyao Vaginosis Drug Product Portfolios and Specifications
13.14.3 Yunnan Baiyao Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Yunnan Baiyao Main Business Overview
13.14.5 Yunnan Baiyao Latest Developments
13.15 Starpharma
13.15.1 Starpharma Company Information
13.15.2 Starpharma Vaginosis Drug Product Portfolios and Specifications
13.15.3 Starpharma Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Starpharma Main Business Overview
13.15.5 Starpharma Latest Developments
13.16 Novel
13.16.1 Novel Company Information
13.16.2 Novel Vaginosis Drug Product Portfolios and Specifications
13.16.3 Novel Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Novel Main Business Overview
13.16.5 Novel Latest Developments
13.17 Edenvridge
13.17.1 Edenvridge Company Information
13.17.2 Edenvridge Vaginosis Drug Product Portfolios and Specifications
13.17.3 Edenvridge Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Edenvridge Main Business Overview
13.17.5 Edenvridge Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaginosis Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Vaginosis Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Vaginosis Drug by Country/Region, 2020, 2024 & 2031
2.2 Vaginosis Drug Segment by Type
2.2.1 Rx
2.2.2 OTC
2.3 Vaginosis Drug Sales by Type
2.3.1 Global Vaginosis Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Vaginosis Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Vaginosis Drug Sale Price by Type (2020-2025)
2.4 Vaginosis Drug Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Other
2.5 Vaginosis Drug Sales by Application
2.5.1 Global Vaginosis Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Vaginosis Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Vaginosis Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Vaginosis Drug Breakdown Data by Company
3.1.1 Global Vaginosis Drug Annual Sales by Company (2020-2025)
3.1.2 Global Vaginosis Drug Sales Market Share by Company (2020-2025)
3.2 Global Vaginosis Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Vaginosis Drug Revenue by Company (2020-2025)
3.2.2 Global Vaginosis Drug Revenue Market Share by Company (2020-2025)
3.3 Global Vaginosis Drug Sale Price by Company
3.4 Key Manufacturers Vaginosis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaginosis Drug Product Location Distribution
3.4.2 Players Vaginosis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VAGINOSIS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Vaginosis Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Vaginosis Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Vaginosis Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Vaginosis Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Vaginosis Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Vaginosis Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Vaginosis Drug Sales Growth
4.4 APAC Vaginosis Drug Sales Growth
4.5 Europe Vaginosis Drug Sales Growth
4.6 Middle East & Africa Vaginosis Drug Sales Growth
5 AMERICAS
5.1 Americas Vaginosis Drug Sales by Country
5.1.1 Americas Vaginosis Drug Sales by Country (2020-2025)
5.1.2 Americas Vaginosis Drug Revenue by Country (2020-2025)
5.2 Americas Vaginosis Drug Sales by Type (2020-2025)
5.3 Americas Vaginosis Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaginosis Drug Sales by Region
6.1.1 APAC Vaginosis Drug Sales by Region (2020-2025)
6.1.2 APAC Vaginosis Drug Revenue by Region (2020-2025)
6.2 APAC Vaginosis Drug Sales by Type (2020-2025)
6.3 APAC Vaginosis Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaginosis Drug by Country
7.1.1 Europe Vaginosis Drug Sales by Country (2020-2025)
7.1.2 Europe Vaginosis Drug Revenue by Country (2020-2025)
7.2 Europe Vaginosis Drug Sales by Type (2020-2025)
7.3 Europe Vaginosis Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaginosis Drug by Country
8.1.1 Middle East & Africa Vaginosis Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Vaginosis Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Vaginosis Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Vaginosis Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaginosis Drug
10.3 Manufacturing Process Analysis of Vaginosis Drug
10.4 Industry Chain Structure of Vaginosis Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaginosis Drug Distributors
11.3 Vaginosis Drug Customer
12 WORLD FORECAST REVIEW FOR VAGINOSIS DRUG BY GEOGRAPHIC REGION
12.1 Global Vaginosis Drug Market Size Forecast by Region
12.1.1 Global Vaginosis Drug Forecast by Region (2026-2031)
12.1.2 Global Vaginosis Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Vaginosis Drug Forecast by Type (2026-2031)
12.7 Global Vaginosis Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 Bayer
13.1.1 Bayer Company Information
13.1.2 Bayer Vaginosis Drug Product Portfolios and Specifications
13.1.3 Bayer Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Bayer Main Business Overview
13.1.5 Bayer Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Vaginosis Drug Product Portfolios and Specifications
13.2.3 Pfizer Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Vaginosis Drug Product Portfolios and Specifications
13.3.3 Sanofi Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Piramal
13.4.1 Piramal Company Information
13.4.2 Piramal Vaginosis Drug Product Portfolios and Specifications
13.4.3 Piramal Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Piramal Main Business Overview
13.4.5 Piramal Latest Developments
13.5 Abbott
13.5.1 Abbott Company Information
13.5.2 Abbott Vaginosis Drug Product Portfolios and Specifications
13.5.3 Abbott Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Abbott Main Business Overview
13.5.5 Abbott Latest Developments
13.6 Galderma
13.6.1 Galderma Company Information
13.6.2 Galderma Vaginosis Drug Product Portfolios and Specifications
13.6.3 Galderma Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Galderma Main Business Overview
13.6.5 Galderma Latest Developments
13.7 Mission
13.7.1 Mission Company Information
13.7.2 Mission Vaginosis Drug Product Portfolios and Specifications
13.7.3 Mission Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Mission Main Business Overview
13.7.5 Mission Latest Developments
13.8 Alkem
13.8.1 Alkem Company Information
13.8.2 Alkem Vaginosis Drug Product Portfolios and Specifications
13.8.3 Alkem Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Alkem Main Business Overview
13.8.5 Alkem Latest Developments
13.9 Xiuzheng
13.9.1 Xiuzheng Company Information
13.9.2 Xiuzheng Vaginosis Drug Product Portfolios and Specifications
13.9.3 Xiuzheng Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Xiuzheng Main Business Overview
13.9.5 Xiuzheng Latest Developments
13.10 Teva
13.10.1 Teva Company Information
13.10.2 Teva Vaginosis Drug Product Portfolios and Specifications
13.10.3 Teva Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Teva Main Business Overview
13.10.5 Teva Latest Developments
13.11 Perrigo
13.11.1 Perrigo Company Information
13.11.2 Perrigo Vaginosis Drug Product Portfolios and Specifications
13.11.3 Perrigo Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Perrigo Main Business Overview
13.11.5 Perrigo Latest Developments
13.12 West-Ward
13.12.1 West-Ward Company Information
13.12.2 West-Ward Vaginosis Drug Product Portfolios and Specifications
13.12.3 West-Ward Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 West-Ward Main Business Overview
13.12.5 West-Ward Latest Developments
13.13 HPGC
13.13.1 HPGC Company Information
13.13.2 HPGC Vaginosis Drug Product Portfolios and Specifications
13.13.3 HPGC Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 HPGC Main Business Overview
13.13.5 HPGC Latest Developments
13.14 Yunnan Baiyao
13.14.1 Yunnan Baiyao Company Information
13.14.2 Yunnan Baiyao Vaginosis Drug Product Portfolios and Specifications
13.14.3 Yunnan Baiyao Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Yunnan Baiyao Main Business Overview
13.14.5 Yunnan Baiyao Latest Developments
13.15 Starpharma
13.15.1 Starpharma Company Information
13.15.2 Starpharma Vaginosis Drug Product Portfolios and Specifications
13.15.3 Starpharma Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Starpharma Main Business Overview
13.15.5 Starpharma Latest Developments
13.16 Novel
13.16.1 Novel Company Information
13.16.2 Novel Vaginosis Drug Product Portfolios and Specifications
13.16.3 Novel Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Novel Main Business Overview
13.16.5 Novel Latest Developments
13.17 Edenvridge
13.17.1 Edenvridge Company Information
13.17.2 Edenvridge Vaginosis Drug Product Portfolios and Specifications
13.17.3 Edenvridge Vaginosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Edenvridge Main Business Overview
13.17.5 Edenvridge Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Vaginosis Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Vaginosis Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Rx
Table 4. Major Players of OTC
Table 5. Global Vaginosis Drug Sales by Type (2020-2025) & (K Doses)
Table 6. Global Vaginosis Drug Sales Market Share by Type (2020-2025)
Table 7. Global Vaginosis Drug Revenue by Type (2020-2025) & ($ million)
Table 8. Global Vaginosis Drug Revenue Market Share by Type (2020-2025)
Table 9. Global Vaginosis Drug Sale Price by Type (2020-2025) & (USD/Dose)
Table 10. Global Vaginosis Drug Sale by Application (2020-2025) & (K Doses)
Table 11. Global Vaginosis Drug Sale Market Share by Application (2020-2025)
Table 12. Global Vaginosis Drug Revenue by Application (2020-2025) & ($ million)
Table 13. Global Vaginosis Drug Revenue Market Share by Application (2020-2025)
Table 14. Global Vaginosis Drug Sale Price by Application (2020-2025) & (USD/Dose)
Table 15. Global Vaginosis Drug Sales by Company (2020-2025) & (K Doses)
Table 16. Global Vaginosis Drug Sales Market Share by Company (2020-2025)
Table 17. Global Vaginosis Drug Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Vaginosis Drug Revenue Market Share by Company (2020-2025)
Table 19. Global Vaginosis Drug Sale Price by Company (2020-2025) & (USD/Dose)
Table 20. Key Manufacturers Vaginosis Drug Producing Area Distribution and Sales Area
Table 21. Players Vaginosis Drug Products Offered
Table 22. Vaginosis Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Vaginosis Drug Sales by Geographic Region (2020-2025) & (K Doses)
Table 26. Global Vaginosis Drug Sales Market Share Geographic Region (2020-2025)
Table 27. Global Vaginosis Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Vaginosis Drug Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Vaginosis Drug Sales by Country/Region (2020-2025) & (K Doses)
Table 30. Global Vaginosis Drug Sales Market Share by Country/Region (2020-2025)
Table 31. Global Vaginosis Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Vaginosis Drug Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Vaginosis Drug Sales by Country (2020-2025) & (K Doses)
Table 34. Americas Vaginosis Drug Sales Market Share by Country (2020-2025)
Table 35. Americas Vaginosis Drug Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Vaginosis Drug Sales by Type (2020-2025) & (K Doses)
Table 37. Americas Vaginosis Drug Sales by Application (2020-2025) & (K Doses)
Table 38. APAC Vaginosis Drug Sales by Region (2020-2025) & (K Doses)
Table 39. APAC Vaginosis Drug Sales Market Share by Region (2020-2025)
Table 40. APAC Vaginosis Drug Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Vaginosis Drug Sales by Type (2020-2025) & (K Doses)
Table 42. APAC Vaginosis Drug Sales by Application (2020-2025) & (K Doses)
Table 43. Europe Vaginosis Drug Sales by Country (2020-2025) & (K Doses)
Table 44. Europe Vaginosis Drug Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Vaginosis Drug Sales by Type (2020-2025) & (K Doses)
Table 46. Europe Vaginosis Drug Sales by Application (2020-2025) & (K Doses)
Table 47. Middle East & Africa Vaginosis Drug Sales by Country (2020-2025) & (K Doses)
Table 48. Middle East & Africa Vaginosis Drug Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Vaginosis Drug Sales by Type (2020-2025) & (K Doses)
Table 50. Middle East & Africa Vaginosis Drug Sales by Application (2020-2025) & (K Doses)
Table 51. Key Market Drivers & Growth Opportunities of Vaginosis Drug
Table 52. Key Market Challenges & Risks of Vaginosis Drug
Table 53. Key Industry Trends of Vaginosis Drug
Table 54. Vaginosis Drug Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Vaginosis Drug Distributors List
Table 57. Vaginosis Drug Customer List
Table 58. Global Vaginosis Drug Sales Forecast by Region (2026-2031) & (K Doses)
Table 59. Global Vaginosis Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Vaginosis Drug Sales Forecast by Country (2026-2031) & (K Doses)
Table 61. Americas Vaginosis Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Vaginosis Drug Sales Forecast by Region (2026-2031) & (K Doses)
Table 63. APAC Vaginosis Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Vaginosis Drug Sales Forecast by Country (2026-2031) & (K Doses)
Table 65. Europe Vaginosis Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Vaginosis Drug Sales Forecast by Country (2026-2031) & (K Doses)
Table 67. Middle East & Africa Vaginosis Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Vaginosis Drug Sales Forecast by Type (2026-2031) & (K Doses)
Table 69. Global Vaginosis Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Vaginosis Drug Sales Forecast by Application (2026-2031) & (K Doses)
Table 71. Global Vaginosis Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Bayer Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 73. Bayer Vaginosis Drug Product Portfolios and Specifications
Table 74. Bayer Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 75. Bayer Main Business
Table 76. Bayer Latest Developments
Table 77. Pfizer Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 78. Pfizer Vaginosis Drug Product Portfolios and Specifications
Table 79. Pfizer Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 80. Pfizer Main Business
Table 81. Pfizer Latest Developments
Table 82. Sanofi Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 83. Sanofi Vaginosis Drug Product Portfolios and Specifications
Table 84. Sanofi Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 85. Sanofi Main Business
Table 86. Sanofi Latest Developments
Table 87. Piramal Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 88. Piramal Vaginosis Drug Product Portfolios and Specifications
Table 89. Piramal Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 90. Piramal Main Business
Table 91. Piramal Latest Developments
Table 92. Abbott Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 93. Abbott Vaginosis Drug Product Portfolios and Specifications
Table 94. Abbott Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 95. Abbott Main Business
Table 96. Abbott Latest Developments
Table 97. Galderma Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 98. Galderma Vaginosis Drug Product Portfolios and Specifications
Table 99. Galderma Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 100. Galderma Main Business
Table 101. Galderma Latest Developments
Table 102. Mission Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 103. Mission Vaginosis Drug Product Portfolios and Specifications
Table 104. Mission Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 105. Mission Main Business
Table 106. Mission Latest Developments
Table 107. Alkem Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 108. Alkem Vaginosis Drug Product Portfolios and Specifications
Table 109. Alkem Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 110. Alkem Main Business
Table 111. Alkem Latest Developments
Table 112. Xiuzheng Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 113. Xiuzheng Vaginosis Drug Product Portfolios and Specifications
Table 114. Xiuzheng Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 115. Xiuzheng Main Business
Table 116. Xiuzheng Latest Developments
Table 117. Teva Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 118. Teva Vaginosis Drug Product Portfolios and Specifications
Table 119. Teva Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 120. Teva Main Business
Table 121. Teva Latest Developments
Table 122. Perrigo Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 123. Perrigo Vaginosis Drug Product Portfolios and Specifications
Table 124. Perrigo Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 125. Perrigo Main Business
Table 126. Perrigo Latest Developments
Table 127. West-Ward Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 128. West-Ward Vaginosis Drug Product Portfolios and Specifications
Table 129. West-Ward Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 130. West-Ward Main Business
Table 131. West-Ward Latest Developments
Table 132. HPGC Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 133. HPGC Vaginosis Drug Product Portfolios and Specifications
Table 134. HPGC Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 135. HPGC Main Business
Table 136. HPGC Latest Developments
Table 137. Yunnan Baiyao Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 138. Yunnan Baiyao Vaginosis Drug Product Portfolios and Specifications
Table 139. Yunnan Baiyao Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 140. Yunnan Baiyao Main Business
Table 141. Yunnan Baiyao Latest Developments
Table 142. Starpharma Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 143. Starpharma Vaginosis Drug Product Portfolios and Specifications
Table 144. Starpharma Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 145. Starpharma Main Business
Table 146. Starpharma Latest Developments
Table 147. Novel Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 148. Novel Vaginosis Drug Product Portfolios and Specifications
Table 149. Novel Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 150. Novel Main Business
Table 151. Novel Latest Developments
Table 152. Edenvridge Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 153. Edenvridge Vaginosis Drug Product Portfolios and Specifications
Table 154. Edenvridge Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 155. Edenvridge Main Business
Table 156. Edenvridge Latest Developments
Table 1. Vaginosis Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Vaginosis Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Rx
Table 4. Major Players of OTC
Table 5. Global Vaginosis Drug Sales by Type (2020-2025) & (K Doses)
Table 6. Global Vaginosis Drug Sales Market Share by Type (2020-2025)
Table 7. Global Vaginosis Drug Revenue by Type (2020-2025) & ($ million)
Table 8. Global Vaginosis Drug Revenue Market Share by Type (2020-2025)
Table 9. Global Vaginosis Drug Sale Price by Type (2020-2025) & (USD/Dose)
Table 10. Global Vaginosis Drug Sale by Application (2020-2025) & (K Doses)
Table 11. Global Vaginosis Drug Sale Market Share by Application (2020-2025)
Table 12. Global Vaginosis Drug Revenue by Application (2020-2025) & ($ million)
Table 13. Global Vaginosis Drug Revenue Market Share by Application (2020-2025)
Table 14. Global Vaginosis Drug Sale Price by Application (2020-2025) & (USD/Dose)
Table 15. Global Vaginosis Drug Sales by Company (2020-2025) & (K Doses)
Table 16. Global Vaginosis Drug Sales Market Share by Company (2020-2025)
Table 17. Global Vaginosis Drug Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Vaginosis Drug Revenue Market Share by Company (2020-2025)
Table 19. Global Vaginosis Drug Sale Price by Company (2020-2025) & (USD/Dose)
Table 20. Key Manufacturers Vaginosis Drug Producing Area Distribution and Sales Area
Table 21. Players Vaginosis Drug Products Offered
Table 22. Vaginosis Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Vaginosis Drug Sales by Geographic Region (2020-2025) & (K Doses)
Table 26. Global Vaginosis Drug Sales Market Share Geographic Region (2020-2025)
Table 27. Global Vaginosis Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Vaginosis Drug Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Vaginosis Drug Sales by Country/Region (2020-2025) & (K Doses)
Table 30. Global Vaginosis Drug Sales Market Share by Country/Region (2020-2025)
Table 31. Global Vaginosis Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Vaginosis Drug Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Vaginosis Drug Sales by Country (2020-2025) & (K Doses)
Table 34. Americas Vaginosis Drug Sales Market Share by Country (2020-2025)
Table 35. Americas Vaginosis Drug Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Vaginosis Drug Sales by Type (2020-2025) & (K Doses)
Table 37. Americas Vaginosis Drug Sales by Application (2020-2025) & (K Doses)
Table 38. APAC Vaginosis Drug Sales by Region (2020-2025) & (K Doses)
Table 39. APAC Vaginosis Drug Sales Market Share by Region (2020-2025)
Table 40. APAC Vaginosis Drug Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Vaginosis Drug Sales by Type (2020-2025) & (K Doses)
Table 42. APAC Vaginosis Drug Sales by Application (2020-2025) & (K Doses)
Table 43. Europe Vaginosis Drug Sales by Country (2020-2025) & (K Doses)
Table 44. Europe Vaginosis Drug Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Vaginosis Drug Sales by Type (2020-2025) & (K Doses)
Table 46. Europe Vaginosis Drug Sales by Application (2020-2025) & (K Doses)
Table 47. Middle East & Africa Vaginosis Drug Sales by Country (2020-2025) & (K Doses)
Table 48. Middle East & Africa Vaginosis Drug Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Vaginosis Drug Sales by Type (2020-2025) & (K Doses)
Table 50. Middle East & Africa Vaginosis Drug Sales by Application (2020-2025) & (K Doses)
Table 51. Key Market Drivers & Growth Opportunities of Vaginosis Drug
Table 52. Key Market Challenges & Risks of Vaginosis Drug
Table 53. Key Industry Trends of Vaginosis Drug
Table 54. Vaginosis Drug Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Vaginosis Drug Distributors List
Table 57. Vaginosis Drug Customer List
Table 58. Global Vaginosis Drug Sales Forecast by Region (2026-2031) & (K Doses)
Table 59. Global Vaginosis Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Vaginosis Drug Sales Forecast by Country (2026-2031) & (K Doses)
Table 61. Americas Vaginosis Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Vaginosis Drug Sales Forecast by Region (2026-2031) & (K Doses)
Table 63. APAC Vaginosis Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Vaginosis Drug Sales Forecast by Country (2026-2031) & (K Doses)
Table 65. Europe Vaginosis Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Vaginosis Drug Sales Forecast by Country (2026-2031) & (K Doses)
Table 67. Middle East & Africa Vaginosis Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Vaginosis Drug Sales Forecast by Type (2026-2031) & (K Doses)
Table 69. Global Vaginosis Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Vaginosis Drug Sales Forecast by Application (2026-2031) & (K Doses)
Table 71. Global Vaginosis Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Bayer Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 73. Bayer Vaginosis Drug Product Portfolios and Specifications
Table 74. Bayer Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 75. Bayer Main Business
Table 76. Bayer Latest Developments
Table 77. Pfizer Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 78. Pfizer Vaginosis Drug Product Portfolios and Specifications
Table 79. Pfizer Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 80. Pfizer Main Business
Table 81. Pfizer Latest Developments
Table 82. Sanofi Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 83. Sanofi Vaginosis Drug Product Portfolios and Specifications
Table 84. Sanofi Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 85. Sanofi Main Business
Table 86. Sanofi Latest Developments
Table 87. Piramal Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 88. Piramal Vaginosis Drug Product Portfolios and Specifications
Table 89. Piramal Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 90. Piramal Main Business
Table 91. Piramal Latest Developments
Table 92. Abbott Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 93. Abbott Vaginosis Drug Product Portfolios and Specifications
Table 94. Abbott Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 95. Abbott Main Business
Table 96. Abbott Latest Developments
Table 97. Galderma Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 98. Galderma Vaginosis Drug Product Portfolios and Specifications
Table 99. Galderma Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 100. Galderma Main Business
Table 101. Galderma Latest Developments
Table 102. Mission Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 103. Mission Vaginosis Drug Product Portfolios and Specifications
Table 104. Mission Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 105. Mission Main Business
Table 106. Mission Latest Developments
Table 107. Alkem Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 108. Alkem Vaginosis Drug Product Portfolios and Specifications
Table 109. Alkem Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 110. Alkem Main Business
Table 111. Alkem Latest Developments
Table 112. Xiuzheng Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 113. Xiuzheng Vaginosis Drug Product Portfolios and Specifications
Table 114. Xiuzheng Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 115. Xiuzheng Main Business
Table 116. Xiuzheng Latest Developments
Table 117. Teva Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 118. Teva Vaginosis Drug Product Portfolios and Specifications
Table 119. Teva Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 120. Teva Main Business
Table 121. Teva Latest Developments
Table 122. Perrigo Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 123. Perrigo Vaginosis Drug Product Portfolios and Specifications
Table 124. Perrigo Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 125. Perrigo Main Business
Table 126. Perrigo Latest Developments
Table 127. West-Ward Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 128. West-Ward Vaginosis Drug Product Portfolios and Specifications
Table 129. West-Ward Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 130. West-Ward Main Business
Table 131. West-Ward Latest Developments
Table 132. HPGC Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 133. HPGC Vaginosis Drug Product Portfolios and Specifications
Table 134. HPGC Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 135. HPGC Main Business
Table 136. HPGC Latest Developments
Table 137. Yunnan Baiyao Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 138. Yunnan Baiyao Vaginosis Drug Product Portfolios and Specifications
Table 139. Yunnan Baiyao Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 140. Yunnan Baiyao Main Business
Table 141. Yunnan Baiyao Latest Developments
Table 142. Starpharma Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 143. Starpharma Vaginosis Drug Product Portfolios and Specifications
Table 144. Starpharma Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 145. Starpharma Main Business
Table 146. Starpharma Latest Developments
Table 147. Novel Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 148. Novel Vaginosis Drug Product Portfolios and Specifications
Table 149. Novel Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 150. Novel Main Business
Table 151. Novel Latest Developments
Table 152. Edenvridge Basic Information, Vaginosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 153. Edenvridge Vaginosis Drug Product Portfolios and Specifications
Table 154. Edenvridge Vaginosis Drug Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 155. Edenvridge Main Business
Table 156. Edenvridge Latest Developments
LIST OF FIGURES
Figure 1. Picture of Vaginosis Drug
Figure 2. Vaginosis Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaginosis Drug Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Vaginosis Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Vaginosis Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Vaginosis Drug Sales Market Share by Country/Region (2024)
Figure 10. Vaginosis Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Rx
Figure 12. Product Picture of OTC
Figure 13. Global Vaginosis Drug Sales Market Share by Type in 2025
Figure 14. Global Vaginosis Drug Revenue Market Share by Type (2020-2025)
Figure 15. Vaginosis Drug Consumed in Hospital
Figure 16. Global Vaginosis Drug Market: Hospital (2020-2025) & (K Doses)
Figure 17. Vaginosis Drug Consumed in Pharmacy
Figure 18. Global Vaginosis Drug Market: Pharmacy (2020-2025) & (K Doses)
Figure 19. Vaginosis Drug Consumed in Other
Figure 20. Global Vaginosis Drug Market: Other (2020-2025) & (K Doses)
Figure 21. Global Vaginosis Drug Sale Market Share by Application (2024)
Figure 22. Global Vaginosis Drug Revenue Market Share by Application in 2025
Figure 23. Vaginosis Drug Sales by Company in 2025 (K Doses)
Figure 24. Global Vaginosis Drug Sales Market Share by Company in 2025
Figure 25. Vaginosis Drug Revenue by Company in 2025 ($ millions)
Figure 26. Global Vaginosis Drug Revenue Market Share by Company in 2025
Figure 27. Global Vaginosis Drug Sales Market Share by Geographic Region (2020-2025)
Figure 28. Global Vaginosis Drug Revenue Market Share by Geographic Region in 2025
Figure 29. Americas Vaginosis Drug Sales 2020-2025 (K Doses)
Figure 30. Americas Vaginosis Drug Revenue 2020-2025 ($ millions)
Figure 31. APAC Vaginosis Drug Sales 2020-2025 (K Doses)
Figure 32. APAC Vaginosis Drug Revenue 2020-2025 ($ millions)
Figure 33. Europe Vaginosis Drug Sales 2020-2025 (K Doses)
Figure 34. Europe Vaginosis Drug Revenue 2020-2025 ($ millions)
Figure 35. Middle East & Africa Vaginosis Drug Sales 2020-2025 (K Doses)
Figure 36. Middle East & Africa Vaginosis Drug Revenue 2020-2025 ($ millions)
Figure 37. Americas Vaginosis Drug Sales Market Share by Country in 2025
Figure 38. Americas Vaginosis Drug Revenue Market Share by Country (2020-2025)
Figure 39. Americas Vaginosis Drug Sales Market Share by Type (2020-2025)
Figure 40. Americas Vaginosis Drug Sales Market Share by Application (2020-2025)
Figure 41. United States Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 42. Canada Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 43. Mexico Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Brazil Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. APAC Vaginosis Drug Sales Market Share by Region in 2025
Figure 46. APAC Vaginosis Drug Revenue Market Share by Region (2020-2025)
Figure 47. APAC Vaginosis Drug Sales Market Share by Type (2020-2025)
Figure 48. APAC Vaginosis Drug Sales Market Share by Application (2020-2025)
Figure 49. China Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 50. Japan Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 51. South Korea Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. Southeast Asia Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. India Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Australia Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. China Taiwan Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Europe Vaginosis Drug Sales Market Share by Country in 2025
Figure 57. Europe Vaginosis Drug Revenue Market Share by Country (2020-2025)
Figure 58. Europe Vaginosis Drug Sales Market Share by Type (2020-2025)
Figure 59. Europe Vaginosis Drug Sales Market Share by Application (2020-2025)
Figure 60. Germany Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 61. France Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 62. UK Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 63. Italy Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. Russia Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Middle East & Africa Vaginosis Drug Sales Market Share by Country (2020-2025)
Figure 66. Middle East & Africa Vaginosis Drug Sales Market Share by Type (2020-2025)
Figure 67. Middle East & Africa Vaginosis Drug Sales Market Share by Application (2020-2025)
Figure 68. Egypt Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. South Africa Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 70. Israel Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. Turkey Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. GCC Countries Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Vaginosis Drug in 2025
Figure 74. Manufacturing Process Analysis of Vaginosis Drug
Figure 75. Industry Chain Structure of Vaginosis Drug
Figure 76. Channels of Distribution
Figure 77. Global Vaginosis Drug Sales Market Forecast by Region (2026-2031)
Figure 78. Global Vaginosis Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 79. Global Vaginosis Drug Sales Market Share Forecast by Type (2026-2031)
Figure 80. Global Vaginosis Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 81. Global Vaginosis Drug Sales Market Share Forecast by Application (2026-2031)
Figure 82. Global Vaginosis Drug Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Vaginosis Drug
Figure 2. Vaginosis Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaginosis Drug Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Vaginosis Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Vaginosis Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Vaginosis Drug Sales Market Share by Country/Region (2024)
Figure 10. Vaginosis Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Rx
Figure 12. Product Picture of OTC
Figure 13. Global Vaginosis Drug Sales Market Share by Type in 2025
Figure 14. Global Vaginosis Drug Revenue Market Share by Type (2020-2025)
Figure 15. Vaginosis Drug Consumed in Hospital
Figure 16. Global Vaginosis Drug Market: Hospital (2020-2025) & (K Doses)
Figure 17. Vaginosis Drug Consumed in Pharmacy
Figure 18. Global Vaginosis Drug Market: Pharmacy (2020-2025) & (K Doses)
Figure 19. Vaginosis Drug Consumed in Other
Figure 20. Global Vaginosis Drug Market: Other (2020-2025) & (K Doses)
Figure 21. Global Vaginosis Drug Sale Market Share by Application (2024)
Figure 22. Global Vaginosis Drug Revenue Market Share by Application in 2025
Figure 23. Vaginosis Drug Sales by Company in 2025 (K Doses)
Figure 24. Global Vaginosis Drug Sales Market Share by Company in 2025
Figure 25. Vaginosis Drug Revenue by Company in 2025 ($ millions)
Figure 26. Global Vaginosis Drug Revenue Market Share by Company in 2025
Figure 27. Global Vaginosis Drug Sales Market Share by Geographic Region (2020-2025)
Figure 28. Global Vaginosis Drug Revenue Market Share by Geographic Region in 2025
Figure 29. Americas Vaginosis Drug Sales 2020-2025 (K Doses)
Figure 30. Americas Vaginosis Drug Revenue 2020-2025 ($ millions)
Figure 31. APAC Vaginosis Drug Sales 2020-2025 (K Doses)
Figure 32. APAC Vaginosis Drug Revenue 2020-2025 ($ millions)
Figure 33. Europe Vaginosis Drug Sales 2020-2025 (K Doses)
Figure 34. Europe Vaginosis Drug Revenue 2020-2025 ($ millions)
Figure 35. Middle East & Africa Vaginosis Drug Sales 2020-2025 (K Doses)
Figure 36. Middle East & Africa Vaginosis Drug Revenue 2020-2025 ($ millions)
Figure 37. Americas Vaginosis Drug Sales Market Share by Country in 2025
Figure 38. Americas Vaginosis Drug Revenue Market Share by Country (2020-2025)
Figure 39. Americas Vaginosis Drug Sales Market Share by Type (2020-2025)
Figure 40. Americas Vaginosis Drug Sales Market Share by Application (2020-2025)
Figure 41. United States Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 42. Canada Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 43. Mexico Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 44. Brazil Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 45. APAC Vaginosis Drug Sales Market Share by Region in 2025
Figure 46. APAC Vaginosis Drug Revenue Market Share by Region (2020-2025)
Figure 47. APAC Vaginosis Drug Sales Market Share by Type (2020-2025)
Figure 48. APAC Vaginosis Drug Sales Market Share by Application (2020-2025)
Figure 49. China Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 50. Japan Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 51. South Korea Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 52. Southeast Asia Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 53. India Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Australia Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. China Taiwan Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Europe Vaginosis Drug Sales Market Share by Country in 2025
Figure 57. Europe Vaginosis Drug Revenue Market Share by Country (2020-2025)
Figure 58. Europe Vaginosis Drug Sales Market Share by Type (2020-2025)
Figure 59. Europe Vaginosis Drug Sales Market Share by Application (2020-2025)
Figure 60. Germany Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 61. France Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 62. UK Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 63. Italy Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 64. Russia Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. Middle East & Africa Vaginosis Drug Sales Market Share by Country (2020-2025)
Figure 66. Middle East & Africa Vaginosis Drug Sales Market Share by Type (2020-2025)
Figure 67. Middle East & Africa Vaginosis Drug Sales Market Share by Application (2020-2025)
Figure 68. Egypt Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. South Africa Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 70. Israel Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 71. Turkey Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 72. GCC Countries Vaginosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Vaginosis Drug in 2025
Figure 74. Manufacturing Process Analysis of Vaginosis Drug
Figure 75. Industry Chain Structure of Vaginosis Drug
Figure 76. Channels of Distribution
Figure 77. Global Vaginosis Drug Sales Market Forecast by Region (2026-2031)
Figure 78. Global Vaginosis Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 79. Global Vaginosis Drug Sales Market Share Forecast by Type (2026-2031)
Figure 80. Global Vaginosis Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 81. Global Vaginosis Drug Sales Market Share Forecast by Application (2026-2031)
Figure 82. Global Vaginosis Drug Revenue Market Share Forecast by Application (2026-2031)
More Publications
United States Bacterial Vaginosis Drug Market by Manufacturers, States, Type and Application, Forecast to 2022
US$ 4,480.00
June 2017
117 pages
